Dinakar Singh

20,000 kids, so it's a lot of people, but they're SMA-specific.

These regeneration drugs will actually help lots of people.

And it's ironic because SMA is actually becoming a poster child for this because cake muscle is an example.

I assume that there'd be tons of people and experts that knew all about muscle development from muscle stem cells called satellite cells into muscles, et cetera.

There may be six people in this country that know what they're talking about when it comes to muscle.

It's crazy.

I assume, well, gosh, if you've got A-Rod and steroids and all that kind of stuff, I mean, there must be big money in it.

But the reality is muscle has been a really tough field for a couple of interesting reasons.

There are two types of people that have muscle problems.

People with degenerative diseases like SMA, muscular dystrophy, et cetera, or on the other side, old, weak people.

Old, weak people are a disaster to go and do trials on.

And you're trying to see what a moderate impact you make when there's such decline happening.

And so clinical trials, and this is the problem with Alzheimer's, are very, very challenging in elderly, degenerating parents.

And in that first category, people with muscular disease, until SMA, none of them had been solved.

And so it's a bit like that boat that you haven't fixed the hole in in the first place.

SMA is now becoming this really fascinating area because suddenly if you have an idea for a muscle drug, you can actually test an SMA and actually see whether it actually does something because now you've fixed that boat, if you will.

And so it is funny, quite a difference from 20 years ago.

And no one cared.

Now, suddenly, we're calling up people saying, look, we think there's an idea.

Your drug didn't really work here.